,Neonatal qand qPediatric qRespiratory qCare, q6th qEdition, qBrian qK. qWalsh qTest qBank
Table qof qContents
Chapter q1. qFetal qLung qDevelopment
Chapter q2. qFetal qGas qExchange qand qCirculation
Chapter q3. qAntenatal qAssessment qand qHigh-Risk qDelivery
Chapter q4. qExamination qand qAssessment qof qthe qNeonatal qand qPediatric qPatient
Chapter q5. qPulmonary qFunction qTesting qand qBedside qPulmonary qMechanics
Chapter q6. qRadiographic qAssessment
Chapter q7. qPediatric qFlexible qBronchoscopy
Chapter q8. qInvasive qBlood qGas qAnalysis qand qCardiovascular qMonitoring
Chapter q9. qNoninvasive qMonitoring qin qNeonatal qand qPediatric qCare
Chapter q10. qOxygen qAdministration
Chapter q11. qAerosols qand qAdministration qof qInhaled qMedications
Chapter q12. qAirway qClearance qTechniques qand qHyperinflation qTherapy
Chapter q13. qAirway qManagement
Chapter q14. qSurfactant qReplacement qTherapy
Chapter q15. qNoninvasive qMechanical qVentilation qand qContinuous qPositive qPressure qof qthe
qNeonate
Chapter q16. qNoninvasive qMechanical qVentilation qof qthe qInfant qand qChild
Chapter q17. qInvasive qMechanical qVentilation qof qthe qNeonate qand qPediatric qPatient
Chapter q18. qAdministration qof qGas qMixtures
Chapter q19. qExtracorporeal qMembrane qOxygenation
Chapter q20. qPharmacology
Chapter q21. qThoracic qOrgan qTransplantation
Chapter q22. qNeonatal qPulmonary qDisorders
Chapter q23. qSurgical qDisorders qin qChildhood qthat qAffect qRespiratory qCare
Chapter q24. qCongenital qCardiac qDefects
Chapter q25. qPediatric qSleep-Disordered qBreathing
Chapter q26. qPediatric qAirway qDisorders qand qParenchymal qLung qDiseases
Chapter q27. qAsthma
Chapter q28. qCystic qFibrosis
Chapter q29. qAcute qRespiratory qDistress qSyndrome
Chapter q30. qShock
Chapter q31. qPediatric qTrauma
Chapter q32. qDisorders qof qthe qPleura
Chapter q33. qNeurological qand qNeuromuscular qDisorders
Chapter q34. qPediatric qEmergencies
Chapter q35. qHome qCare qof qthe qPostpartum qFamily
Chapter q36. qQuality qand qSafety
,Chapter q1: qFetal qLung qDevelopment
Walsh: qNeonatal q& qPediatric qRespiratory qCare q6th qEdition qTest qBank q
MULTIPLE qCHOICE
1. Which qof qthe qfollowing qphases qof qhuman qlung qdevelopment qis qcharacterized qby qthe
qformation qof qa qcapillary qnetwork qaround qairway qpassages?
a. Pseudoglandular
b. Saccular
c. Alveolar
d. Canalicular
ANS: q D
The qcanalicular qphase qfollows qthe qpseudoglandular qphase, qlasting qfrom qapproximately q17
qweeks qto q26 qweeks qof qgestation. qThis qphase qis qso qnamed qbecause qof qthe qappearance qof
qvascular qchannels, qor qcapillaries, qwhich qbegin qto qgrow qby qforming qa qcapillary qnetwork
qaround qthe qair qpassages. qDuring qthe qpseudoglandular qstage, qwhich qbegins qat qday q52 qand
qextends qto qweek q16 qof qgestation, qthe qairway qsystem qsubdivides qextensively qand qthe
qconducting qairway qsystem qdevelops, qending qwith qthe qterminal qbronchioles. qThe qsaccular
qstage qof qdevelopment, qwhich qtakes qplace qfrom qweeks q29 qto q36 qof qgestation, qis
qcharacterized qby qthe qdevelopment qof qsacs qthat qlater qbecome qalveoli. qDuring qthe qsaccular
qphase, qa qtremendous qincrease qin qthe qpotential qgas- qexchanging qsurface qarea qoccurs. qThe
qdistinction qbetween qthe qsaccular qstage qand qthe qalveolar qstage qis qarbitrary. qThe qalveolar
qstage qstretches qfrom q39 qweeks qof qgestation qto qterm. qThis qstage qis qrepresented qby qthe
qestablishment qof qalveoli.
REF: qpp. q 3-5
2. Regarding qpostnatal qlung qgrowth, qby qapproximately qwhat qage qdo qmost qof qthe qalveoli qthat
qwill qbe qpresent qin qthe qlungs qfor qlife qdevelop?
a. 6 qmonths
b. 1 qyear
c. 1.5 qyears
d. 2 qyears
ANS: q C
Most qof qthe qpostnatal qformation qof qalveoli qin qthe qinfant qoccurs qover qthe qfirst q1.5 qyears qof
qlife. qAt q2 qyears qof qage, qthe qnumber qof qalveoli qvaries qsubstantially qamong qindividuals. qAfter
q2 qyears qof qage, qmales qhave qmore qalveoli qthan qdo qfemales. qAfter qalveolar qmultiplication
qends, qthe qalveoli qcontinue qto qincrease qin qsize quntil qthoracic qgrowth qis qcompleted.
REF: q p. q6
3. The qrespiratory qtherapist qis qevaluating qa qnewborn qwith qmild qrespiratory qdistress qdue qto
qtracheal qstenosis. qDuring qwhich qperiod qof qlung qdevelopment qdid qthis qproblem qdevelop?
, a. Embryonal
b. Saccular
c. Canalicular
d. Alveolar
ANS: q A
The qinitial qstructures qof qthe qpulmonary qtree qdevelop qduring qthe qembryonal qstage. qErrors qin
qdevelopment qduring qthis qtime qmay qresult qin qlaryngeal, qtracheal, qor qesophageal qatresia qor
qstenosis. qPulmonary qhypoplasia, qan qincomplete qdevelopment qof qthe qlungs qcharacterized qby
qan qabnormally qlow qnumber qand/or qsize qof qbronchopulmonary qsegments qand/or qalveoli,
qcan qdevelop qduring qthe qpseudoglandular qphase. qIf qthe qfetus qis qborn qduring qthe qcanalicular
qphase q(i.e., qprematurely), qsevere qrespiratory qdistress qcan qbe qexpected qbecause qthe
qinadequately qdeveloped qairways, qalong qwith qinsufficient qand qimmature qsurfactant
qproduction qby qalveolar qtype qII qcells, qgives qrise qto qthe qconstellation qof qproblems qknown qas
qinfant qrespiratory qdistress qsyndrome.
REF: q q p. q6
4. Which qof qthe qfollowing qmechanisms qis q(are) qresponsible qfor qthe qpossible qassociation
qbetween qoligohydramnios qand qlung qhypoplasia?
I. Abnormal qcarbohydrate qmetabolism
II. Mechanical qrestriction qof qthe qchest qwall
III. Interference qwith qfetal qbreathing
IV. Failure qto qproduce qfetal qlung qliquid
a. I qand q III qonly
b. II qand q III qonly
c. I, qII, qand qIV qonly
d. II, qIII, qand qIV qonly
ANS: q D
Oligohydramnios, qa qreduced qquantity qof qamniotic qfluid qpresent qfor qan qextended qperiod qof
qtime, qwith qor qwithout qrenal qanomalies, qis qassociated qwith qlung qhypoplasia. qThe
qmechanisms qby qwhich qamniotic qfluid qvolume qinfluences qlung qgrowth qremain qunclear.
qPossible qexplanations qfor qreduced qquantity qof qamniotic qfluid qinclude qmechanical qrestriction
qof qthe qchest qwall, qinterference qwith qfetal qbreathing, qor qfailure qto qproduce qfetal qlung qliquid.
qThese qclinical qand qexperimental qobservations qpossibly qpoint qto qa qcommon qdenominator,
qlung qstretch, qas qbeing qa qmajor qgrowth qstimulant.
REF: qpp. q6-7
5. What qis qthe qpurpose qof qthe qsubstance qsecreted qby qthe qtype qII qpneumocyte?
a. To qincrease qthe qgas qexchange qsurface qarea
b. To qreduce qsurface qtension
c. To qmaintain qlung qelasticity
d. To qpreserve qthe qvolume qof qthe qamniotic qfluid
Table qof qContents
Chapter q1. qFetal qLung qDevelopment
Chapter q2. qFetal qGas qExchange qand qCirculation
Chapter q3. qAntenatal qAssessment qand qHigh-Risk qDelivery
Chapter q4. qExamination qand qAssessment qof qthe qNeonatal qand qPediatric qPatient
Chapter q5. qPulmonary qFunction qTesting qand qBedside qPulmonary qMechanics
Chapter q6. qRadiographic qAssessment
Chapter q7. qPediatric qFlexible qBronchoscopy
Chapter q8. qInvasive qBlood qGas qAnalysis qand qCardiovascular qMonitoring
Chapter q9. qNoninvasive qMonitoring qin qNeonatal qand qPediatric qCare
Chapter q10. qOxygen qAdministration
Chapter q11. qAerosols qand qAdministration qof qInhaled qMedications
Chapter q12. qAirway qClearance qTechniques qand qHyperinflation qTherapy
Chapter q13. qAirway qManagement
Chapter q14. qSurfactant qReplacement qTherapy
Chapter q15. qNoninvasive qMechanical qVentilation qand qContinuous qPositive qPressure qof qthe
qNeonate
Chapter q16. qNoninvasive qMechanical qVentilation qof qthe qInfant qand qChild
Chapter q17. qInvasive qMechanical qVentilation qof qthe qNeonate qand qPediatric qPatient
Chapter q18. qAdministration qof qGas qMixtures
Chapter q19. qExtracorporeal qMembrane qOxygenation
Chapter q20. qPharmacology
Chapter q21. qThoracic qOrgan qTransplantation
Chapter q22. qNeonatal qPulmonary qDisorders
Chapter q23. qSurgical qDisorders qin qChildhood qthat qAffect qRespiratory qCare
Chapter q24. qCongenital qCardiac qDefects
Chapter q25. qPediatric qSleep-Disordered qBreathing
Chapter q26. qPediatric qAirway qDisorders qand qParenchymal qLung qDiseases
Chapter q27. qAsthma
Chapter q28. qCystic qFibrosis
Chapter q29. qAcute qRespiratory qDistress qSyndrome
Chapter q30. qShock
Chapter q31. qPediatric qTrauma
Chapter q32. qDisorders qof qthe qPleura
Chapter q33. qNeurological qand qNeuromuscular qDisorders
Chapter q34. qPediatric qEmergencies
Chapter q35. qHome qCare qof qthe qPostpartum qFamily
Chapter q36. qQuality qand qSafety
,Chapter q1: qFetal qLung qDevelopment
Walsh: qNeonatal q& qPediatric qRespiratory qCare q6th qEdition qTest qBank q
MULTIPLE qCHOICE
1. Which qof qthe qfollowing qphases qof qhuman qlung qdevelopment qis qcharacterized qby qthe
qformation qof qa qcapillary qnetwork qaround qairway qpassages?
a. Pseudoglandular
b. Saccular
c. Alveolar
d. Canalicular
ANS: q D
The qcanalicular qphase qfollows qthe qpseudoglandular qphase, qlasting qfrom qapproximately q17
qweeks qto q26 qweeks qof qgestation. qThis qphase qis qso qnamed qbecause qof qthe qappearance qof
qvascular qchannels, qor qcapillaries, qwhich qbegin qto qgrow qby qforming qa qcapillary qnetwork
qaround qthe qair qpassages. qDuring qthe qpseudoglandular qstage, qwhich qbegins qat qday q52 qand
qextends qto qweek q16 qof qgestation, qthe qairway qsystem qsubdivides qextensively qand qthe
qconducting qairway qsystem qdevelops, qending qwith qthe qterminal qbronchioles. qThe qsaccular
qstage qof qdevelopment, qwhich qtakes qplace qfrom qweeks q29 qto q36 qof qgestation, qis
qcharacterized qby qthe qdevelopment qof qsacs qthat qlater qbecome qalveoli. qDuring qthe qsaccular
qphase, qa qtremendous qincrease qin qthe qpotential qgas- qexchanging qsurface qarea qoccurs. qThe
qdistinction qbetween qthe qsaccular qstage qand qthe qalveolar qstage qis qarbitrary. qThe qalveolar
qstage qstretches qfrom q39 qweeks qof qgestation qto qterm. qThis qstage qis qrepresented qby qthe
qestablishment qof qalveoli.
REF: qpp. q 3-5
2. Regarding qpostnatal qlung qgrowth, qby qapproximately qwhat qage qdo qmost qof qthe qalveoli qthat
qwill qbe qpresent qin qthe qlungs qfor qlife qdevelop?
a. 6 qmonths
b. 1 qyear
c. 1.5 qyears
d. 2 qyears
ANS: q C
Most qof qthe qpostnatal qformation qof qalveoli qin qthe qinfant qoccurs qover qthe qfirst q1.5 qyears qof
qlife. qAt q2 qyears qof qage, qthe qnumber qof qalveoli qvaries qsubstantially qamong qindividuals. qAfter
q2 qyears qof qage, qmales qhave qmore qalveoli qthan qdo qfemales. qAfter qalveolar qmultiplication
qends, qthe qalveoli qcontinue qto qincrease qin qsize quntil qthoracic qgrowth qis qcompleted.
REF: q p. q6
3. The qrespiratory qtherapist qis qevaluating qa qnewborn qwith qmild qrespiratory qdistress qdue qto
qtracheal qstenosis. qDuring qwhich qperiod qof qlung qdevelopment qdid qthis qproblem qdevelop?
, a. Embryonal
b. Saccular
c. Canalicular
d. Alveolar
ANS: q A
The qinitial qstructures qof qthe qpulmonary qtree qdevelop qduring qthe qembryonal qstage. qErrors qin
qdevelopment qduring qthis qtime qmay qresult qin qlaryngeal, qtracheal, qor qesophageal qatresia qor
qstenosis. qPulmonary qhypoplasia, qan qincomplete qdevelopment qof qthe qlungs qcharacterized qby
qan qabnormally qlow qnumber qand/or qsize qof qbronchopulmonary qsegments qand/or qalveoli,
qcan qdevelop qduring qthe qpseudoglandular qphase. qIf qthe qfetus qis qborn qduring qthe qcanalicular
qphase q(i.e., qprematurely), qsevere qrespiratory qdistress qcan qbe qexpected qbecause qthe
qinadequately qdeveloped qairways, qalong qwith qinsufficient qand qimmature qsurfactant
qproduction qby qalveolar qtype qII qcells, qgives qrise qto qthe qconstellation qof qproblems qknown qas
qinfant qrespiratory qdistress qsyndrome.
REF: q q p. q6
4. Which qof qthe qfollowing qmechanisms qis q(are) qresponsible qfor qthe qpossible qassociation
qbetween qoligohydramnios qand qlung qhypoplasia?
I. Abnormal qcarbohydrate qmetabolism
II. Mechanical qrestriction qof qthe qchest qwall
III. Interference qwith qfetal qbreathing
IV. Failure qto qproduce qfetal qlung qliquid
a. I qand q III qonly
b. II qand q III qonly
c. I, qII, qand qIV qonly
d. II, qIII, qand qIV qonly
ANS: q D
Oligohydramnios, qa qreduced qquantity qof qamniotic qfluid qpresent qfor qan qextended qperiod qof
qtime, qwith qor qwithout qrenal qanomalies, qis qassociated qwith qlung qhypoplasia. qThe
qmechanisms qby qwhich qamniotic qfluid qvolume qinfluences qlung qgrowth qremain qunclear.
qPossible qexplanations qfor qreduced qquantity qof qamniotic qfluid qinclude qmechanical qrestriction
qof qthe qchest qwall, qinterference qwith qfetal qbreathing, qor qfailure qto qproduce qfetal qlung qliquid.
qThese qclinical qand qexperimental qobservations qpossibly qpoint qto qa qcommon qdenominator,
qlung qstretch, qas qbeing qa qmajor qgrowth qstimulant.
REF: qpp. q6-7
5. What qis qthe qpurpose qof qthe qsubstance qsecreted qby qthe qtype qII qpneumocyte?
a. To qincrease qthe qgas qexchange qsurface qarea
b. To qreduce qsurface qtension
c. To qmaintain qlung qelasticity
d. To qpreserve qthe qvolume qof qthe qamniotic qfluid
